NASDAQ:SNTI Senti Biosciences (SNTI) Stock Price, News & Analysis $0.39 -0.03 (-7.14%) (As of 07/2/2024 ET) Add Compare Share Share Today's Range$0.34▼$0.4150-Day Range$0.24▼$0.4252-Week Range$0.21▼$1.09Volume8.64 million shsAverage Volume3.65 million shsMarket Capitalization$17.85 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Senti Biosciences alerts: Email Address Senti Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,438.5% Upside$6.00 Price TargetShort InterestHealthy0.98% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.94Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.27 out of 5 starsMedical Sector484th out of 914 stocksBiological Products, Except Diagnostic Industry75th out of 152 stocks 3.5 Analyst's Opinion Consensus RatingSenti Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageSenti Biosciences has received no research coverage in the past 90 days.Read more about Senti Biosciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.98% of the float of Senti Biosciences has been sold short.Short Interest Ratio / Days to CoverSenti Biosciences has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Senti Biosciences has recently increased by 8.50%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSenti Biosciences does not currently pay a dividend.Dividend GrowthSenti Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SNTI. Previous Next 3.3 News and Social Media Coverage News SentimentSenti Biosciences has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Senti Biosciences this week, compared to 0 articles on an average week.Search Interest5 people have searched for SNTI on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Senti Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Senti Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders15.90% of the stock of Senti Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 25.73% of the stock of Senti Biosciences is held by institutions.Read more about Senti Biosciences' insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Senti Biosciences is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Senti Biosciences is -0.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSenti Biosciences has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Senti Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Senti Biosciences Stock (NASDAQ:SNTI)Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More SNTI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SNTI Stock News HeadlinesJuly 2 at 7:17 AM | marketbeat.comComplete Solaria, Senti, and POET: 3 High Volume Penny StocksHigh volume can indicate market strength, but volume is relative. Thirty million in traded shares doesn't mean much if the average daily volume is higher.July 2 at 7:17 AM | marketbeat.comComplete Solaria, Senti, and POET: 3 High Volume Penny Stocks (SNTI)Penny stocks are risky, but follow the money to find winners. Stocks with significant volume spikes may have what it takes for higher share prices.July 2, 2024 | StockEarnings (Ad)Re: We’re giving you all this for less than a pair of socksThe Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicators... Our all-in-one Premium Membership gives you everything you need to potentially profit in any market. Members have seen gains of 76.2%, 85.6%, and even 111.3% on single trades. This July 4th, get 12 months of access for just $4. July 1 at 8:05 AM | globenewswire.comSenti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell TherapyJune 25, 2024 | investorplace.comWhy Is Senti Biosciences (SNTI) Stock Up 32% Today?May 13, 2024 | finance.yahoo.comSenti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid LeukemiaMay 10, 2024 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate HighlightsMay 10, 2024 | msn.comSenti Biosciences GAAP EPS of -$0.26July 2, 2024 | StockEarnings (Ad)Re: We’re giving you all this for less than a pair of socksThe Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicators... Our all-in-one Premium Membership gives you everything you need to potentially profit in any market. Members have seen gains of 76.2%, 85.6%, and even 111.3% on single trades. This July 4th, get 12 months of access for just $4. May 10, 2024 | investorplace.comSNTI Stock Earnings: Senti Biosciences Reported Results for Q1 2024May 9, 2024 | globenewswire.comSenti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate HighlightsApril 30, 2024 | globenewswire.comSenti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)March 23, 2024 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent HighlightsMarch 21, 2024 | globenewswire.comSenti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent HighlightsFebruary 4, 2024 | benzinga.comSenti Biosciences Stock (NASDAQ:SNTI), Guidance and ForecastJanuary 8, 2024 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical ProgramJanuary 5, 2024 | marketwatch.comSenti Biosciences to Cut Workforce by 37% to Focus on Potential Cancer TreatmentJanuary 5, 2024 | finance.yahoo.comSenti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical ProgramDecember 22, 2023 | finance.yahoo.comWhy Is Blood Cancer Focused Senti Biosciences Stock Trading Higher Today?December 22, 2023 | markets.businessinsider.comSenti Bio : FDA Clears IND Application For SENTI-202 For Treatment Of R/R Hematologic MalignanciesDecember 22, 2023 | finance.yahoo.comSenti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid LeukemiaNovember 24, 2023 | finanznachrichten.deSenti Biosciences, Inc.: Senti Bio Announces Third Quarter 2023 Results and Pipeline UpdatesNovember 13, 2023 | finance.yahoo.comSenti Bio Announces Third Quarter 2023 Results and Pipeline UpdatesNovember 11, 2023 | morningstar.comSenti Biosciences Inc SNTINovember 7, 2023 | msn.comWhy Is Cell & Gene Therapy-Focused Senti Biosciences Stock Trading Higher Today?November 7, 2023 | msn.comWhy Is Ventyx Biosciences (VTYX) Stock Down 76% Today?November 7, 2023 | msn.comWhy Is Senti Biosciences (SNTI) Stock Up 140% Today?See More Headlines Receive SNTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/02/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:SNTI CUSIPN/A CIK1854270 Webwww.sentibio.com Phone650-239-2030FaxN/AEmployees48Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+1,438.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.44) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,060,000.00 Net MarginsN/A Pretax Margin-6,405.10% Return on Equity-79.71% Return on Assets-48.64% Debt Debt-to-Equity RatioN/A Current Ratio5.79 Quick Ratio5.79 Sales & Book Value Annual Sales$2.56 million Price / Sales6.97 Cash FlowN/A Price / Cash FlowN/A Book Value$1.50 per share Price / Book0.26Miscellaneous Outstanding Shares45,760,000Free Float38,480,000Market Cap$17.85 million OptionableNot Optionable Beta2.75 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Timothy K. Lu M.D. (Age 43)Ph.D., Co-founder, CEO, President & Director Comp: $868.57kDr. James J. Collins Ph.D. (Age 58)Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director Comp: $58.5kMs. Susan D. Berland (Age 69)Senior Financial Executive & Independent Director Comp: $57.5kDr. Kanya Rajangam M.D. (Age 50)Ph.D., Head of Research & Development and Chief Medical Officer Comp: $689.99kDr. Wilson Wong Ph.D.Scientific Co-Founder & Member of Scientific Advisory BoardMr. Mike RheeSenior VP of Legal Affairs & Corporate SecretarySusan KahlertControllerMore ExecutivesKey CompetitorsDyadic InternationalNASDAQ:DYAICurisNASDAQ:CRISProtara TherapeuticsNASDAQ:TARAAtara BiotherapeuticsNASDAQ:ATRAIN8bioNASDAQ:INABView All Competitors SNTI Stock Analysis - Frequently Asked Questions Should I buy or sell Senti Biosciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Senti Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SNTI shares. View SNTI analyst ratings or view top-rated stocks. What is Senti Biosciences' stock price target for 2024? 1 equities research analysts have issued 12-month target prices for Senti Biosciences' shares. Their SNTI share price targets range from $6.00 to $6.00. On average, they expect the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 1,438.5% from the stock's current price. View analysts price targets for SNTI or view top-rated stocks among Wall Street analysts. How have SNTI shares performed in 2024? Senti Biosciences' stock was trading at $0.66 at the beginning of 2024. Since then, SNTI stock has decreased by 40.9% and is now trading at $0.39. View the best growth stocks for 2024 here. When is Senti Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our SNTI earnings forecast. How were Senti Biosciences' earnings last quarter? Senti Biosciences, Inc. (NASDAQ:SNTI) announced its quarterly earnings results on Thursday, May, 9th. The company reported ($0.26) earnings per share for the quarter. What ETF holds Senti Biosciences' stock? ARK Genomic Revolution ETF holds 1,565,921 shares of SNTI stock, representing 0.03% of its portfolio. How do I buy shares of Senti Biosciences? Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SNTI) was last updated on 7/2/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveThe internet generated more wealth than any other innovation in history - creating hundreds of thousands of ne...Chaikin Analytics | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredRe: We’re giving you all this for less than a pair of socksThe Only Trading Tool You'll Need This Year Forget juggling multiple subscriptions and confusing indicator...StockEarnings | Sponsored25th AmendmentIt's not surprising that talk of invoking the 25th Amendment (to remove Biden from office) has surfaced.Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored270x more lucrative than NVIDIA???If you've missed out on NVIDIA's recent 1,600% run... Don't worry. Because there's one AI stock that cou...Behind the Markets | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.